International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationBrachytherapy in the Treatment of Cholangiocarcinoma
Introduction
Cholangiocarcinomas are rare malignancies that arise from the epithelial cells that line the bile ducts and constitute approximately 3% of all gastrointestinal cancers (1). Surgical resection is the only curative treatment for cholangiocarcinomas; however, a large proportion of patients are unresectable at the time of diagnosis 2, 3, 4, 5, 6. Optimal adjuvant therapy for resected patients and palliative treatment for unresectable patients remains unclear. Evidence to support treatment recommendations is scant, in large part owing to the low incidence of cholangiocarcinomas, which has precluded large randomized studies examining the role of radiation and chemotherapy.
Brachytherapy is one way radiation can be used to treat cholangiocarcinoma and may improve stent patency and perhaps improve survival 7, 8, 9, 10, 11, 12. Because of the intraluminal growth pattern, positive margins are often seen at the cut biliary duct margin, which may be treated with brachytherapy. Brachytherapy has many advantages in that it allows the delivery of localized radiation that may limit toxicity and allow dose escalation. Hence, brachytherapy can potentially be used as a boost to safely increase the dose delivered in the definitive setting.
It is also important to maintain biliary patency because most patients ultimately die of liver dysfunction due to tumor obstruction of biliary drainage. Some studies have found that biliary stenting is as effective as surgical bypass in providing relief from obstructive jaundice (13). Even in patients with unresectable pancreatic cancer or cholangiocarcinoma, approximately 21% will be alive at 1 year. Hence, long-term solutions for malignant obstructive jaundice are needed, because many patients will survive long enough that reocclusion will be a major problem, even in the setting of unresectable disease (14). Brachytherapy may improve the duration of stent patency and potentially extend survival (15).
The majority of studies that have examined the use of brachytherapy in cholangiocarcinomas are small single-institution studies. In the present study a retrospective analysis of a large group of patients with extrahepatic cholangiocarcinoma (EHC) and intrahepatic cholangiocarcinoma (IHC) treated with brachytherapy was performed using the Surveillance, Epidemiology and End Results (SEER) database.
Section snippets
Patient selection and treatment
The SEER database is a national cancer surveillance program run by the National Cancer Institute that collects information about the incidence and survival of cancer cases from 17 cancer registries throughout the United States. These registries encompass approximately 26% of the United States population and are representative of national demographics. The SEER database was queried for the diagnosis of cholangiocarcinoma from 1988 to 2003. The International Classification of Diseases for
Results
A total of 5345 patients with EHC and 4359 patients with IHC with radiation and surgical data were identified for the period 1988–2003. Of these patients, a total of 43 (0.60% of all patients in this study) were treated with brachytherapy alone, and 150 patients (2.1% of all patients in this study) were treated with a combination of external-beam radiation and brachytherapy. A total of 6859 patients received no radiation. Because of the relatively small number of patients treated with
Discussion
The present study investigates the use of brachytherapy in a large group of patients with cholangiocarcinoma from the SEER database. Results from this analysis demonstrate an improvement in OS when patients were treated with brachytherapy with or without external-beam radiation compared with patients treated without radiation. Subset analysis comparing brachytherapy alone vs. no radiation and brachytherapy combined with external beam radiation vs. no radiation suggested that the survival
References (34)
- et al.
Surgery for hilar cholangiocarcinoma: A 10 year experience of a tertiary referral centre in the UK
Eur J Surg Oncol
(2005) - et al.
Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts
Int J Radiat Oncol Biol Phys
(2003) - et al.
Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: A prospective randomised study
Eur J Radiol
(2007) - et al.
Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma
Int J Radiat Oncol Biol Phys
(2008) - et al.
Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas
Int J Radiat Oncol Biol Phys
(2009) - et al.
Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma
Int J Radiat Oncol Biol Phys
(2003) - et al.
The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer
Int J Radiat Oncol Biol Phys
(1994) - et al.
The role of radiotherapy in the management of extrahepatic bile duct cancer: An analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy
Int J Radiat Oncol Biol Phys
(1996) - et al.
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma
Int J Radiat Oncol Biol Phys
(2009) Cholangiocarcinoma—what level of evidence should we have?
Int J Radiat Oncol Biol Phys
(2009)
Recent advances in the management of cholangiocarcinomas
Semin Liver Dis
Surgical management of intrahepatic cholangiocarcinoma: A population-Based study
Ann Surg Oncol
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors
Ann Surg
Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma
J Surg Oncol
Review article: The modern diagnosis and therapy of cholangiocarcinoma
Aliment Pharmacol Ther
Treatment of malignant biliary obstruction by combined percutaneous transhepatic biliary drainage with local tumor treatment
World J Gastroenterol
Intraluminal brachytherapy with metallic stenting in the palliative treatment of malignant obstruction of the bile duct
Radiat Med
Cited by (41)
Principles and indications of brachytherapy
2022, Nuclear Medicine and Molecular Imaging: Volume 1-4The combination of endoluminal radiofrequency ablation and metal stent implantation for the treatment of malignant biliary stenosis – Randomized study
2021, European Journal of RadiologyCitation Excerpt :Chen et al. in his study achieved a prolonged stent patency rate in the group treated with brachytherapy (12.6 vs 8.3 months), but extended survival did not reach a statistically significant level (median 7.0 vs 6.0 months) [4]. Shinohara et al. in 2010 showed an increased survival rate in brachytherapy group compared to the control group (11 vs 4 months) [5]. Endoluminal radiofrequency ablation (RFA) performed before biliary metal stent placement benefits from its simplicity of use and patient management.
High-dose rate intraluminal brachytherapy: An effective palliation for cholangiocarcinoma causing bile duct obstruction
2018, Surgical OncologyCitation Excerpt :Most of these patients will eventually experience biliary obstruction during the course of their disease and as a result, disabling jaundice, intense pruritus, loss of appetite and weight, acholic stools, painful hepatomegaly, change in bowel habits, nausea, vomiting, coagulopathies and even cholangitis and sepsis [4]. Restoration of bile flow is thus required to prevent complications and because most patients ultimately die of liver dysfunction due to tumour obstruction of biliary drainage [6]. Multiple palliative treatment options are available, such as endoscopic retrograde biliary drainage through sphincterotomy and/or stent placement [7], percutaneous anterograde drainage [8], external beam radiation [9,10], intraluminal brachytherapy (ILBT) [4], palliative chemotherapy [11], surgery [12], photodynamic therapy (PDT) [13] or a combination of these modalities.
Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial
2018, Journal of HepatologyCitation Excerpt :Theoretically, the four lines of radioactive seeds used by the new device in this study should improve dosimetry compared to brachytherapy, with a tube shaking in the biliary tract, described in previous reports. The estimated median radiation dose in this study at the dose reference points calculated by the computerized TPS was approximately 47.0 Gy, which is between the reported dose of 25.0 to 70.0 Gy in traditional brachytherapy with other radioactive sources.36,37 None of brachytherapy-related grade 3 or 4 complications was found in this trial.
Cholangiocarcinoma
2017, Zakim and Boyer's Hepatology: A Textbook of Liver DiseaseHepatobiliary Cancer
2015, Clinical Radiation Oncology
This project was funded, in part, under a grant with the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analysis, interpretations, or conclusions.
Conflict of interest: none.